Neurocrine Biosciences, Inc. (NBIX)
NBIX Stock Price Chart
Explore Neurocrine Biosciences, Inc. interactive price chart. Choose custom timeframes to analyze NBIX price movements and trends.
NBIX Company Profile
Discover essential business fundamentals and corporate details for Neurocrine Biosciences, Inc. (NBIX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
23 May 1996
Employees
1.80K
Website
https://www.neurocrine.comCEO
Kyle W. Gano
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.
NBIX Financial Timeline
Browse a chronological timeline of Neurocrine Biosciences, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 4 May 2026
Upcoming earnings on 4 Feb 2026
Upcoming earnings on 29 Oct 2025
EPS estimate is $1.55, while revenue estimate is $745.76M.
Earnings released on 30 Jul 2025
EPS came in at $1.06 surpassing the estimated $0.98 by +8.16%, while revenue for the quarter reached $687.50M , missing expectations by -7.89%.
Earnings released on 5 May 2025
EPS came in at $0.08 falling short of the estimated $0.54 by -85.05%, while revenue for the quarter reached $572.60M , beating expectations by +2.32%.
Earnings released on 6 Feb 2025
EPS came in at $1.00 falling short of the estimated $1.62 by -38.27%, while revenue for the quarter reached $627.70M , missing expectations by -0.28%.
Earnings released on 30 Oct 2024
EPS came in at $1.24 falling short of the estimated $1.51 by -17.88%, while revenue for the quarter reached $622.10M , beating expectations by +3.57%.
Earnings released on 1 Aug 2024
EPS came in at $0.63 falling short of the estimated $1.05 by -40.00%, while revenue for the quarter reached $590.20M , beating expectations by +8.11%.
Earnings released on 1 May 2024
EPS came in at $0.42 falling short of the estimated $1.01 by -58.42%, while revenue for the quarter reached $515.30M , beating expectations by +0.57%.
Earnings released on 7 Feb 2024
EPS came in at $1.44 surpassing the estimated $1.15 by +25.22%, while revenue for the quarter reached $515.20M , missing expectations by -0.76%.
Earnings released on 31 Oct 2023
EPS came in at $0.82 falling short of the estimated $0.97 by -15.46%, while revenue for the quarter reached $498.80M , beating expectations by +6.55%.
Earnings released on 1 Aug 2023
EPS came in at $0.95 surpassing the estimated $0.78 by +21.79%, while revenue for the quarter reached $452.70M , beating expectations by +1.20%.
Earnings released on 3 May 2023
EPS came in at -$0.79 falling short of the estimated $0.26 by -403.85%, while revenue for the quarter reached $420.40M , beating expectations by +2.72%.
Earnings released on 6 Feb 2023
EPS came in at $0.88 falling short of the estimated $1.16 by -24.14%, while revenue for the quarter reached $412.00M , beating expectations by +0.77%.
Earnings released on 1 Nov 2022
EPS came in at $0.69 falling short of the estimated $0.79 by -12.66%, while revenue for the quarter reached $387.90M , beating expectations by +2.89%.
Earnings released on 4 Aug 2022
EPS came in at -$0.18 falling short of the estimated $0.56 by -132.14%, while revenue for the quarter reached $378.20M , beating expectations by +10.48%.
Earnings released on 4 May 2022
EPS came in at $0.14 falling short of the estimated $0.35 by -60.00%, while revenue for the quarter reached $310.60M , beating expectations by +2.15%.
Earnings released on 11 Feb 2022
EPS came in at -$0.08 falling short of the estimated $0.61 by -113.11%, while revenue for the quarter reached $312.00M , missing expectations by -1.73%.
Earnings released on 1 Nov 2021
EPS came in at $0.23 falling short of the estimated $0.51 by -54.90%, while revenue for the quarter reached $296.00M , missing expectations by -0.20%.
Earnings released on 3 Aug 2021
EPS came in at $0.43 falling short of the estimated $0.48 by -10.42%, while revenue for the quarter reached $288.90M , meeting expectations.
Earnings released on 5 May 2021
EPS came in at $0.33 falling short of the estimated $0.51 by -35.29%, while revenue for the quarter reached $236.60M , missing expectations by -6.56%.
Earnings released on 4 Feb 2021
EPS came in at $3.58 surpassing the estimated $0.59 by +506.78%, while revenue for the quarter reached $247.90M , missing expectations by -5.95%.
Earnings released on 9 Nov 2020
EPS came in at -$0.62 falling short of the estimated $0.11 by -663.64%, while revenue for the quarter reached $258.50M , missing expectations by -76.94%.
NBIX Stock Performance
Access detailed NBIX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.